Skip to main content

Research Repository

Advanced Search

Healthcare costs of transarterial chemoembolization in the treatment of hepatocellular carcinoma

Fateen, Waleed; Khan, Farooq; O’Neill, Richard; James, Martin; Ryder, Stephen; Aithal, Guruprasad

Authors

Waleed Fateen

Farooq Khan

Richard O’Neill

Martin James martin.james@nottingham.ac.uk

Stephen Ryder stephen.ryder@nuh.nhs.uk



Abstract

Background: A meta-analysis comparing drug-eluting beads transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (cTACE) has recently been published. On balance, no significant differences were found in terms of objective response and overall survival. The impact on healthcare costs had been studied in small series based on a hypothetical model and was in favor of DEB-TACE. We aimed to evaluate and compare healthcare costs and effectiveness of both modalities in a cohort of patients from Nottingham, UK.
Methods: Using a dedicated radiology database, we identified all patients who had undergone cTACE or DEB-TACE between 2006 and 2012 at a single tertiary referral center based in Nottingham. We collected clinical data, including treatment response, postprocedure complications and 30-day mortality. Costing models were constructed to present both our local hospital perspective as well as the national health service position.
Results: During our study period, 101 procedures were performed on 43 patients (76 cTACE procedures on 26 patients and 25 DEB-TACE procedures on 17 patients). Overall, 11/26 in cTACE and 5/17 in DEB-TACE group had progressive disease (p=0.52). Adverse events were seen in 6/76 cTACE compared with 7/25 DEB-TACE group (p=0.16). Based on the predetermined standard pathway there was an unadjusted average cost difference of £3770.30 (TACE =£9070.44, DEB-TACE =£5300.14) in favor of the DEB-TACE. Results from our costing models indicated a £2715.33 (95% CI £580.88–4849.77) cost difference in favor of the same procedure.
Conclusions: Even when the extra costs of DEB-TACE were considered, the overall treatment costs per patient were lower in relation to cTACE.

Citation

Fateen, W., Khan, F., O’Neill, R., James, M., Ryder, S., & Aithal, G. (2017). Healthcare costs of transarterial chemoembolization in the treatment of hepatocellular carcinoma. Journal of Hepatocellular Carcinoma, 2017(4), https://doi.org/10.2147/JHC.S144068

Journal Article Type Article
Acceptance Date Aug 28, 2017
Publication Date Oct 16, 2017
Deposit Date Feb 19, 2018
Publicly Available Date Feb 19, 2018
Journal Journal of Hepatocellular Carcinoma
Electronic ISSN 2253-5969
Publisher Dove Medical Press
Peer Reviewed Peer Reviewed
Volume 2017
Issue 4
DOI https://doi.org/10.2147/JHC.S144068
Keywords hepatocellular carcinoma, transarterial chemoembolization, healthcare costs, drug-eluting beads, objective response
Public URL http://eprints.nottingham.ac.uk/id/eprint/49862
Publisher URL https://doi.org/10.2147/JHC.S144068
Copyright Statement Copyright information regarding this work can be found at the following address: http://creativecommons.org/licenses/by/4.0

Files

JHC-144068-healthcare-costs-of-trans-arterial-chemo-embolization-in-the_101617.pdf (458 Kb)
PDF

Copyright Statement
Copyright information regarding this work can be found at the following address: http://creativecommons.org/licenses/by/4.0





You might also like



Downloadable Citations